Ethic Inc. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 71,272 shares of the biopharmaceutical company's stock after selling 33,372 shares during the quarter. Ethic Inc.'s holdings in Gilead Sciences were worth $7,931,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of GILD. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Gabelli Funds LLC purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $387,000. NewEdge Advisors LLC raised its position in Gilead Sciences by 63.7% during the fourth quarter. NewEdge Advisors LLC now owns 91,653 shares of the biopharmaceutical company's stock valued at $8,466,000 after acquiring an additional 35,657 shares in the last quarter. First Commonwealth Financial Corp PA purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $210,000. Finally, Commerce Bank raised its position in Gilead Sciences by 1.0% during the fourth quarter. Commerce Bank now owns 73,195 shares of the biopharmaceutical company's stock valued at $6,761,000 after acquiring an additional 701 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded up $0.8710 on Wednesday, reaching $118.8510. The company's stock had a trading volume of 2,995,952 shares, compared to its average volume of 8,296,724. The company has a market capitalization of $147.47 billion, a P/E ratio of 23.79, a PEG ratio of 0.72 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $74.80 and a 52-week high of $121.83. The stock has a 50-day moving average price of $112.14 and a 200-day moving average price of $108.71. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business's revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences's payout ratio is currently 62.95%.
Analysts Set New Price Targets
Several research analysts recently weighed in on GILD shares. Oppenheimer reduced their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research report on Tuesday. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $115.39.
Read Our Latest Report on GILD
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer directly owned 605,725 shares in the company, valued at $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 110,000 shares of company stock valued at $12,349,790. Insiders own 0.27% of the company's stock.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
MarketBeat All Access